| 11.4337 0.244 (2.18%) | 09-14 13:50 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.23 | 1-year : | 20.06 |
| Resists | First : | 14.75 | Second : | 17.18 |
| Pivot price | 12.87  |
|||
| Supports | First : | 10.82 | Second : | 9.01 |
| MAs | MA(5) : | 11.5 |
MA(20) : | 13.1 |
| MA(100) : | 13.06 |
MA(250) : | 9.96 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 6 |
D(3) : | 4.2 |
| RSI | RSI(14): 40.8 |
|||
| 52-week | High : | 17.39 | Low : | 4.86 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ KZIA ] has closed above bottom band by 25.6%. Bollinger Bands are 69.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.43 - 11.5 | 11.5 - 11.57 |
| Low: | 10.68 - 10.76 | 10.76 - 10.83 |
| Close: | 11.07 - 11.19 | 11.19 - 11.3 |
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Wed, 09 Sep 2026
No approved treatments exist for returning brain cancer in children. Kazia starts a trial. - Stock Titan
Wed, 02 Sep 2026
Kazia Therapeutics (NASDAQ: KZIA) Shows 52% Tumor Reduction in Preclinical Colorectal Cancer Model - Kalkine Media
Tue, 01 Sep 2026
BTIG Maintains Kazia Therapeutics(KZIA.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Tue, 01 Sep 2026
BTIG raises Kazia Therapeutics stock price target on trial data By Investing.com - Investing.com India
Fri, 28 Aug 2026
Kazia Therapeutics launches public offering of ADSs and warrants By Investing.com - Investing.com India
Fri, 28 Aug 2026
Kazia Therapeutics prices $40 million public offering - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 9.39e+006 (%) |
| Held by Institutions | 15.4 (%) |
| Shares Short | 740 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.784e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -14 % |
| Return on Assets (ttm) | 641 % |
| Return on Equity (ttm) | -25.8 % |
| Qtrly Rev. Growth | 1.9e+006 % |
| Gross Profit (p.s.) | 145.3 |
| Sales Per Share | -49.73 |
| EBITDA (p.s.) | 883721 |
| Qtrly Earnings Growth | -7.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 1 |
| Price to Book value | 0 |
| Price to Sales | -0.23 |
| Price to Cash Flow | 8.33 |
| Dividend | 0 |
| Forward Dividend | 559160 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|